Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

NASDAQ EVOK opened at $4.43 on Thursday. The stock has a 50 day moving average price of $5.15 and a 200-day moving average price of $5.42. Evoke Pharma has a one year low of $3.54 and a one year high of $17.40. The company has a market capitalization of $6.60 million, a P/E ratio of -0.40 and a beta of 0.36.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.